Product logins

Find logins to all Clarivate products below.


Biosimilars | Current Treatment | Nephrology | US/EU | 2019

Erythropoiesis-stimulating agent (ESA) biosimilars entered the European market a decade ago, but only one ESA—Retacrit—has launched in the United States, and it did not launch until November 2018. Despite the availability of multiple ESA biosimilars for chronic kidney disease (CKD) for several years, their uptake in Europe has varied from country to country, as well as by drug and manufacturer. With new biosimilars expected to soon enter all markets, it is vital to understand why ESA biosimilar uptake varies in Europe and the likely impact of upcoming biosimilar launches in the United States and Europe. We surveyed nephrologists from France, Germany, and the United States to learn about their experience and familiarity with current biosimilars; the drivers of and barriers to these agents’ uptake; and their expectations for novel biosimilars.

Scope:

Markets covered: United States, France, and Germany.

Primary research: Online quantitative survey of 92 nephrologists.

Questions answered:

  • What is the current patient share of CKD biosimilars, and what expectations do nephrologists have for future patient shares?
  • How similar do nephrologists believe biosimilars are to their reference brands?
  • What factors do nephrologists identify as being the key drivers of and barriers to biosimilar uptake?
  • What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
  • What cost reduction is required for a biosimilar to achieve more than a 50% patient share?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Amgen
  • Janssen
  • Johnson & Johnson
  • Medice Arzneimittel Putter
  • Pfizer
  • Roche
  • Sandoz (Novartis)
  • Stada Arzneimittel
  • Vifor Pharma

Key drugs mentioned:

  • Abseamed
  • Aranesp
  • Binocrit
  • Epoetin Alfa Hexal
  • Epogen
  • Eprex/Erypro
  • Mircera
  • NeoRecormon
  • Procrit
  • Retacrit
  • Silapo

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…